A new herbicide mode of action targeting the diaminopimelate (DAP) lysine biosynthesis pathway exclusive to plants and bacteria. Includes MBDTA, the first dual-target herbicidal inhibitor, proven lethal to multiple weed species with no effects on mammalian cells or soil microbes. Seeking validation across grasses and crops.
This research program proposes a novel herbicide mode of action targeting lysine biosynthesis in weeds through inhibition of the diaminopimelate (DAP) pathway. Because the DAP pathway exists only in plants and bacteria, with animals unable to produce their own lysine, selective inhibition is unlikely to harm mammals or beneficial organisms. The program has developed inhibitors of multiple enzymes in the lysine biosynthesis pathway, including MBDTA, the first known dual-target herbicidal inhibitor. Proof-of-concept data demonstrates lethality against Arabidopsis thaliana, annual ryegrass (Lolium rigidum), and wild radish (Raphanus raphanistrum), with high specificity to plants and no observed effects on mammalian cells or soil microbes. The opportunity centers on validating these inhibitors across a broader range of grasses and crops to establish efficacy and selectivity.
The technology is at an advanced early-stage research and proof-of-concept level. Inhibitors of the lysine biosynthesis pathway have been developed and validated for lethality in multiple weed species. Selectivity testing has confirmed safety toward mammalian cells and soil microbes. The next phase involves greenhouse screening against a wider range of grasses to determine efficacy, and crop tolerance studies to establish selectivity. Combination studies with existing herbicides will assess synergistic potential. This validation work will advance the program toward field-ready herbicide candidates with a novel mode of action.
The University of Adelaide was a comprehensive public research university in South Australia, with a city‑centre campus and specialised sites linking teaching, research and translation. Co‑location within Adelaide BioMed City placed teams beside the Royal Adelaide Hospital and SAHMRI, enabling clinical trials, while AIML at Lot Fourteen linked researchers to an innovation district. At the Waite Research Precinct, co‑located partners and infrastructure such as the Plant Accelerator supported industry‑engaged R&D. Research was backed by national funding, including the Australian Research Council and NHMRC. On January 5, 2026 it merged with the University of South Australia to form Adelaide University; these assets now operate within the new institution with dedicated tech transfer support.